Oddly enough, risk bearing entities like insurance companies actually follow financial incentives and want policy holders to take needed drugs. The profiteering bastards.
I was thinking this while reading refurb's comment and pleasantly surprised to get down to yours where its explicitly called out.
PBMs are also pretty competitive and I don't think they make a ton of money either.
As for insurance companies, the ACA put limits on profit.
http://www.google.com/finance?q=NYSE%3AAET&ei=yIswVam_LOuJsg...
So does Humana:
http://www.google.com/finance?q=NYSE%3AHUM&ei=44swVcjiAcSGsg...
And Anthem:
http://www.google.com/finance?q=NYSE%3AANTM&ei=OIwwVYr5OIWDs...
And Pfizer:
http://www.google.com/finance?q=NYSE%3APFE&ei=uYwwVeG2DezwsQ...
And Bayer:
http://www.google.com/finance?q=ETR%3ABAYN&ei=Fo0wVcmsE6qysQ...
And that's without even getting started on the corruption of equipment purchasing:
http://www.washingtonmonthly.com/features/2010/1007.blake.ht...
Or the FDA:
http://www.forbes.com/sites/davidmaris/2012/10/10/fda-recall...
Or even the physician trade union itself:
http://seattlepostglobe.org/2011/03/07/warnings-of-doctor-sh...
(note that the govt. measure causing the shortage of residency slots was supported by the physicians themselves--only to later recant after the damage had been done)
There are some players who have a hard time making an obnoxious profit, sure, but let's not pretend that's the general case.
Those shiny new hospitals going up in your local medical center? That money isn't there because healthcare is so affordable and easy to get.
I agree with your writeup, but I'd like to call this out in particular:
What if all the existing players are the source of the problem?
That's the real trouble facing startups in healthcare: everyone wants to partner with the existing players, but they're all basically profiteering bastards.